Immunotherapy for advanced renal cell cancer

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma

Background:

• Advanced renal cell carcinoma (RCC) presents variable prognoses, with chemotherapy often proving ineffective.
• Immunotherapy shows promise for advanced RCC, yet evidence from small, underpowered trials is limited.

Purpose of the Study:

• To systematically evaluate immunotherapy in advanced RCC.
• To compare high-dose interleukin-2 (IL-2) against alternative treatments.
• To compare interferon-alpha (IFN-α) against alternative treatments.

Main Methods:

• Conducted a comprehensive literature search of multiple databases (MEDLINE, Cancerlit, EMBASE, Cochrane Library) from 1966 to 1999.
• Included randomized controlled trials (RCTs) involving patients with advanced RCC treated with immunotherapy.
• Extracted data on treatment response and survival outcomes from 42 eligible studies involving 4216 patients.

Main Results:

• Interferon-alpha demonstrated a statistically significant survival benefit over control treatments (OR for death at one year = 0.67).
• Pooled analysis showed a persistent survival advantage for interferon-alpha up to 24 months (hazard ratio = 0.78).
• High-dose interleukin-2 efficacy was not validated in controlled randomized studies; no survival benefit was proven for added agents to IL-2 or IFN-α.

Conclusions:

• Interferon-alpha provides a modest survival benefit and should be a standard control in future advanced RCC immunotherapy trials.
• High-dose interleukin-2 requires further validation through robust, controlled randomized studies.